Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zocilurtatug Pelitecan · ZL-1310, YL-212

Antibody-drug conjugate · Kills target cells, directed at delta-like protein 3 (DLL3) · developed by Zai Lab Co.

Phase 3 Most advanced trial
ZLAB Developer
1 Registered trials

What is Zocilurtatug Pelitecan?

Zocilurtatug pelitecan is an antibody-drug conjugate made of a humanized IgG1 monoclonal antibody against DLL3, a Notch pathway protein overexpressed on many cancer cell types, linked to a camptothecin derivative. After binding DLL3-expressing tumor cells and being internalized, the camptothecin payload causes their death. It is being studied in small-cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ZL-1310, YL-212
Drug type
Antibody-drug conjugate
Targets
delta-like protein 3 (DLL3)
Mechanism
Kills target cells, directed at delta-like protein 3 (DLL3)
Pathways
Notch signaling
Therapy area
Oncology
Developer
Zai Lab Co., Ltd. (ZLAB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
947N9WVZ4A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07218146 Phase 3 Small-cell Lung Cancer Recruiting ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Small-cell Lung Cancer

Other drugs acting on DLL3

More from Zai Lab Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the ZLAB page.

Follow ZLAB, the company behind Zocilurtatug Pelitecan

See ZLAB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ZLAB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.